Novo Nordisk vs. Apotex: Rybelsus® ANDA Patent Battle Consolidated in New Jersey

Case Overview

The Parties

The Patents at Issue

This landmark case involved six patents specifically asserted in Case No. 1:26-cv-01730, addressing oral peptide delivery formulations, absorption enhancement technology, and pharmaceutical compositions for semaglutide.

• • US9,278,123 — Oral peptide delivery formulations
• • US10,278,923 — Semaglutide absorption enhancement technology
• • US11,382,957 — Pharmaceutical composition claims
• • US11,833,248 — Formulation-specific claims
• • US12,396,953 — Advanced oral delivery patent
• • US12,514,822 — Most recently issued, filed under Application No. 19/192233

Across both consolidated actions, Novo Nordisk asserts a total of seventeen patents spanning formulation chemistry, absorption enhancement, and pharmaceutical composition.

The Verdict & Legal Analysis

Outcome

Case No. 1:26-cv-01730 terminated through a court-approved stipulation for consolidation with Civil Action No. 1:24-cv-09729. No damages were awarded, and no injunctive relief was granted at this stage. The substantive merits of infringement and patent validity remain pending in the consolidated proceeding.

Verdict Cause Analysis

The operative legal mechanism here is the Hatch-Waxman Act framework, under which an ANDA filer’s Paragraph IV certification — asserting that listed patents are invalid or will not be infringed — constitutes a technical act of infringement sufficient to trigger suit under 35 U.S.C. § 271(e)(2). Novo Nordisk’s decision to file a second, separate complaint upon receiving the R2 ANDA notice reflects strategic patent prosecution alignment. The subsequent consolidation under Federal Rule of Civil Procedure 42 is appropriate where actions involve common questions of law or fact, which the parties explicitly agreed upon.

Legal Significance

Several dimensions of this case merit analytical attention:

Patent Portfolio Layering: Novo Nordisk’s seventeen-patent assertion across two ANDAs exemplifies aggressive Orange Book listing and continuation prosecution strategy, reflecting a multi-generational approach to extend IP coverage as formulation science evolved.

Timing of New Patent Assertions: The inclusion of recently issued patents signals that Novo Nordisk continues to prosecute continuation applications strategically timed to cover generic entrants, a common “evergreening” strategy that will likely face validity scrutiny.

Consolidation as Litigation Efficiency Tool: The parties’ cooperative approach to consolidation, including jointly proposing deadlines and discovery plans, may signal a measured litigation posture on both sides, potentially facilitating future settlement discussions.

Strategic Takeaways

For Patent Holders: File continuation applications covering formulation variants to ensure new ANDA filings trigger additional, recently issued patents. Proactive coordination with opposing counsel on procedural consolidation can reduce litigation costs while preserving substantive positions.

For Accused Infringers: In multi-ANDA scenarios, early identification of overlapping patent families enables coordinated invalidity challenges across IPR petitions and district court defenses. Apotex should evaluate Inter Partes Review petitions targeting the recently issued patents given their potential overlap with prior art.

For R&D Teams: Oral peptide delivery and GLP-1 formulation technology remains densely patented. Freedom-to-operate analyses for any semaglutide-adjacent formulation work must account for continuation patent chains extending into 2024–2025 issuances.